SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Lilly Says Taltz Plus Zepbound Outperformed Taltz Alone in Phase 3b PsA Data

Lilly said 52-week Phase 3b TOGETHER-PsA data showed the combination improved and sustained efficacy.

LLY

Related stories